margetuximab

Home
Ligands
margetuximab

GtoPdb Ligand ID: 8686

Synonyms: Margenza® | margetuximab-cmkb | MGAH-22

margetuximab is an approved drug (FDA (2020))

Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a K_D value is not provided.

No information available.

No information available.

Summary of Clinical Use
Margetuximab was evaluated in clinical trials as a potential treatment for HER2⁺ metastatic breast cancer. Results from the Phase 2/3 MAHOGANY study NCT04082364 were published in December 2020 [1]. In that same month the FDA approved its use (n combination with chemotherapy) to treat HER2⁺ breast cancer based on safety and efficacy data from the SOPHIA study (NCT02492711).

Summary of Clinical Use

Margetuximab was evaluated in clinical trials as a potential treatment for HER2⁺ metastatic breast cancer. Results from the Phase 2/3 MAHOGANY study NCT04082364 were published in December 2020 [1]. In that same month the FDA approved its use (n combination with chemotherapy) to treat HER2⁺ breast cancer based on safety and efficacy data from the SOPHIA study (NCT02492711).

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02492711	Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	Phase 3 Interventional	MacroGenics